- Report
- August 2023
- 80 Pages
Africa
From €4250EUR$4,750USD£3,635GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4250EUR$4,750USD£3,635GBP
- Report
- August 2023
- 110 Pages
Global
From €4250EUR$4,750USD£3,635GBP
- Report
- August 2023
- 80 Pages
Africa, Middle East
From €4250EUR$4,750USD£3,635GBP
- Report
- August 2023
- 150 Pages
North America
From €4250EUR$4,750USD£3,635GBP
- Report
- October 2022
- 70 Pages
Africa
From €4250EUR$4,750USD£3,635GBP
- Report
- May 2026
- 200 Pages
Canada
From €2495EUR$2,789USD£2,134GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2495EUR$2,789USD£2,134GBP
- Report
- June 2025
- 400 Pages
Global
From €4428EUR$4,949USD£3,787GBP
- Report
- August 2024
- 150 Pages
Global
From €2495EUR$2,789USD£2,134GBP
- Report
- May 2023
- 147 Pages
Global
From €4428EUR$4,949USD£3,787GBP
- Report
- March 2026
- 136 Pages
France
From €2683EUR$2,999USD£2,295GBP
€3578EUR$3,999USD£3,060GBP
- Report
- May 2024
- 140 Pages
Global
From €2683EUR$2,999USD£2,295GBP
€3578EUR$3,999USD£3,060GBP
- Report
- June 2025
- 138 Pages
Global
From €3534EUR$3,950USD£3,022GBP
- Report
- March 2026
- 150 Pages
Germany
From €4340EUR$4,850USD£3,711GBP
- Report
- March 2026
- 150 Pages
India
From €4340EUR$4,850USD£3,711GBP
- Report
- March 2026
- 150 Pages
Canada
From €4340EUR$4,850USD£3,711GBP
- Report
- March 2026
- 150 Pages
China
From €4340EUR$4,850USD£3,711GBP
- Report
- July 2025
- 150 Pages
Global
From €4340EUR$4,850USD£3,711GBP
- Report
- June 2025
- 97 Pages
Asia Pacific
From €3534EUR$3,950USD£3,022GBP

Sulfonylureas are a class of drugs used to treat type 2 diabetes. They work by stimulating the pancreas to produce more insulin, which helps the body to better process glucose. They are usually taken orally, and are often used in combination with other diabetes medications. Sulfonylureas are generally well-tolerated, but can cause side effects such as hypoglycemia, weight gain, and gastrointestinal upset.
The sulfonylureas market is a subset of the larger diabetes drugs market. It is a competitive market, with a range of products available from different manufacturers. The market is expected to grow in the coming years, driven by increasing prevalence of diabetes and the development of new drugs.
Some of the major companies in the sulfonylureas market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more